Streetbeat News

Regulatory

The FAA released a report criticizing Boeing's safety culture, highlighting a disconnect in understanding and commitment to safety across the company's hierarchy. This follows a recent incident involving an Alaska Airlines flight and ongoing scrutiny after two fatal 737 Max crashes. The report, which includes 27 findings and 53 recommendations, mandates Boeing to create a detailed action plan to address these issues within six months. Boeing's stock showed minimal movement following the report's release.

Portfolio Pulse from Piero Cingari

February 26, 2024 | 9:13 pm

ACB

CRLBF

CURLF

GTBIF

HITI

TCNNF

TLRY

Following Germany's decision to legalize limited cannabis possession, U.S. and Canadian cannabis stocks like Curaleaf Holdings, Trulieve Cannabis Corp., Green Thumb Industries, Cresco Labs, Tilray, and Aurora Cannabis saw movements in their stock prices. Analysts predict significant growth potential in the German market, comparing it to Florida's medical cannabis market. Companies like Tilray and Aurora Cannabis, already established in Germany, are well-positioned to benefit. Curaleaf's affiliate owns a German importer, and High Tide Inc. expressed enthusiasm about entering the German market.

Portfolio Pulse from Maureen Meehan

February 26, 2024 | 9:13 pm

AZN

FGEN

FibroGen and AstraZeneca have mutually agreed to terminate their collaboration agreement on Roxadustat, which was initially entered into on July 30, 2013. As a result, FibroGen regains all rights to Roxadustat in the United States and other AstraZeneca territories, with the exception of China and South Korea.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:06 pm

SPY

U.S. Senate Republican Leader McConnell has assured that the federal government will not shut down, according to Reuters. This statement comes amidst concerns over potential government closures that could impact various sectors of the economy.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:58 pm

ACI

The National Grocers Association has expressed support for the FTC's challenge of the Kroger and Albertsons merger, indicating a desire for further action to level the playing field in the grocery sector.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:57 pm

ACI

AMZN

COST

WMT

The FTC has filed a lawsuit to block Kroger's $25 billion bid for Albertsons, citing concerns over higher food prices and lower wages. Shares of Kroger fell 1.7%, while Albertsons rose 0.6%. Kroger argues the merger would allow it to compete more effectively with giants like Walmart and Costco, and has vowed to defend the merger in court.

Portfolio Pulse from Neil Dennis

February 26, 2024 | 8:16 pm

AHG

Akso Health Group has filed for a mixed shelf offering with the SEC, allowing it to issue up to $400 million in securities. This strategic move could provide the company with flexible financing options for future growth, acquisitions, or debt management.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 7:51 pm

GOOG

GOOGL

MSFT

Google has intensified its criticism of Microsoft, cautioning about the potential monopoly Microsoft could establish in the cloud computing sector. This move by Google highlights the increasing competition and concerns regarding market dominance in the rapidly growing cloud services industry.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 7:44 pm

ACON

AKLI

FRPT

HOLO

VERO

ZVSA

Freshpet, Inc. (NASDAQ:FRPT) shares surged 15.5% after reporting Q4 earnings and sales above estimates. Other stocks also moved significantly in Monday's mid-day session, with notable gainers including Akili, Inc. (NASDAQ:AKLI), ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), and MicroCloud Hologram Inc. (NASDAQ:HOLO), among others. Losers included Aclarion, Inc. (NASDAQ:ACON) and Venus Concept Inc. (NASDAQ:VERO).

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 6:57 pm

BMRN

BioMarin Pharmaceutical Inc. has complied with a subpoena from the U.S. Department of Justice requesting documents related to its testing programs for VIMIZIM and NAGLAZYME. The company cannot predict the outcome of the investigation or its impact on its business or financial statements.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 6:52 pm